Difference between revisions of "Profiles"

From QIBA Wiki
Jump to: navigation, search
(Stage 1: Public Comment Profiles)
 
(20 intermediate revisions by 2 users not shown)
Line 14: Line 14:
  
 
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
 
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
 
  
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
  
* [[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
+
*[[Media:QIBA_CT_Lung_Density_Profile_090420-clean.pdf | QIBA CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
 +
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]
 +
 
 +
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
 +
 
 +
*[[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
  
 
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]]  
 
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]]  
  
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]]  
+
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]  
  
 
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
 
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
Line 34: Line 38:
  
 
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 +
:*[[Media:QIBA_CTA_Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]]
  
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]  
+
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
  
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
  
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
+
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']'''
  
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] (<font color=##00cc00>'''Open for comment: June 26, 2020 - Thursday, October 29, 2020 [extended]'''</font>)
+
*[[Media:QIBA_DCE-MRI_Profile-Stage_1-Public_Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''closed''' on March 10, 2021)
  
*[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29]] ('''closed''' on May 15, 2020)
+
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020)
  
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA_US_SWS_Profile_03.19.2021-clean version.pdf|US Shear Wave Speed for Liver Fibrosis 2021-03-19]] (clean version - Consensus vote)
 +
*[[Media:QIBA_US_SWS_Profile_03.19.2021-with edits.pdf|US Shear Wave Speed for Liver Fibrosis 2021-03-19]] (version with edits for Consensus vote)
  
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019)
+
:*[[Media:SWS Checklists-Appendix E-03.19.2021.xlsx|Appendix E: SWS Checklists]] (updated March 19, 2021)
 
+
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | CT Lung Density 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019)
+
 
+
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] ('''closed''' on October 16, 2019)
+
  
 
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
 
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
Line 68: Line 70:
  
 
: QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
 
: QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
 +
  
 
====Statements of Endorsement====
 
====Statements of Endorsement====
Line 73: Line 76:
 
*[[Clinical Sites]]
 
*[[Clinical Sites]]
 
*[[Additional letters of support can be found here]]
 
*[[Additional letters of support can be found here]]
 +
  
 
====See Also====
 
====See Also====

Latest revision as of 16:28, 6 April 2021

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

  • Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
  • Assessment Procedures (refer to Section 4 in the Profile document - pg 30)


Stage 2: Consensus Profiles


Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also